DPT Laboratories

DPT Laboratories

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DPT Laboratories is a long-established, U.S.-based CDMO with deep expertise in complex semi-solid and liquid drug delivery formats such as creams, ointments, gels, lotions, aerosols, and sprays. As a Viatris company, it offers a fully integrated service model from early-stage formulation development through clinical trial supplies and commercial manufacturing, emphasizing seamless technology transfers. Its core value proposition lies in its specialized technical capabilities in these dosage forms and its ability to guide products from development to commercialization within a single organization.

Drug DeliveryPharmaceutical Manufacturing

Technology Platform

Integrated CDMO platform specializing in the formulation, analytical development, and cGMP manufacturing of semi-solid and liquid dosage forms (creams, ointments, gels, lotions, aerosols, sprays, solutions, suspensions). Capabilities span pre-formulation, process development, clinical trial supply manufacturing, technology transfer, and commercial-scale production.

Opportunities

The growing trend of pharmaceutical outsourcing and the complexity of modern drug formulations, particularly in dermatology and topical delivery, create strong demand for specialized CDMO expertise.
DPT is well-positioned to capture commercial manufacturing contracts through technology transfers as large pharma continues to streamline operations and outsource production.

Risk Factors

As a subsidiary, strategic dependence on parent company Viatris's priorities is a key risk.
The competitive CDMO landscape and potential regulatory compliance issues at its manufacturing facility could also impact operations and reputation.
Its niche focus, while a strength, could limit growth if market demand shifts.

Competitive Landscape

DPT competes in the specialized CDMO segment for semi-solids and liquids against other niche players and larger, diversified CDMOs that offer similar services. Its primary competitive advantages are its deep, 80+ year technical expertise in these specific dosage forms and its fully integrated, single-site service model from development to commercial manufacturing.